For the roughly 1 to 2 percent of pancreatic-cancer patients whose tumors carry a specific genetic glitch called KRAS G12C, ...

Eight people who had surgery for pancreatic cancer and then received a vaccine built from their own tumor DNA have now gone ...

A cancer-killing virus has stopped pancreatic tumours from growing and spreading in three people in an initial safety trial, ...

Pancreatic cancer is notoriously lethal. But new treatments mean that may be changing, and people with the disease now have more reason to hope than ever before.

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit explains why we are in a new era of progress against pancreatic ...

Researchers from the University of Houston and University of Michigan in Ann Arbor have developed a dual-target drug designed to overcome immunotherapy resistance in pancreatic cancer. The research ...

In clinical trials, the drug was shown to almost double the survival time for pancreatic cancer patients. Here's how it works and who can get it.

First-in-human pancreatic cancer trial at WVU tests an implant that delivers chemotherapy directly into tumors using low-voltage electric pulses. The WVU Cancer Institute is helping lead a global ...

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

A new daily pill called daraxonrasib is showing promise against advanced pancreatic cancer in a first-in-human trial of 168 patients with RAS mutations.

The director of the University of Nebraska Medical Center’s Pancreatic Cancer Center of Excellence filed a complaint this week against the University of Nebraska, alleging that leaders ...